CVS Health Corp vs Royal Bank of Canada — how do they compare? CVS Health Corp trades at $86.93 (market cap $112.29B), while Royal Bank of Canada trades at $191.26 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 2.3× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Royal Bank of Canada for 47 Days on average.
| CVS | RY | |
|---|---|---|
Market Cap | $112.29B | $262.99B |
Volume | 7,763,676 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $110.60 | $217.87 |
52-Week Low | $70.08 | $143.64 |
Typical Hold Time | 83 Days | 47 Days |
Enterprise Value | $174.64B | $730.11B |
Dividend Yield | 3.03% | 2.66% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.
CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.
Royal Bank of Canada (RY) trades at $191.33, up 0.06% on the day, with a bearish technical signal and key support at $189. The company reported strong earnings, beating estimates for three consecutive quarters, with Q3 2026 EPS of $3.07 versus $2.89 expected. Revenue grew to $66.53B in 2025, and net income margin improved to 32.01%. Analyst sentiment is mixed, with 43% buy ratings but technical indicators showing selling pressure.
RY's outlook is supported by solid profitability and dividend payments, but faces risks from stretched valuations and negative cash flow trends. The stock's current bearish technical stance and high debt levels warrant caution, though institutional interest remains. Upside depends on sustained earnings growth and effective cost management amid economic uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →